Analyst Price Target is $17.75
▲ +163.74% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Provention Bio in the last 3 months. The average price target is $17.75, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 163.74% upside from the last price of $6.73.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Provention Bio. This Buy consensus rating has held steady for over two years.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.